What is the patent status for Ozempic and Wegovy going into 2026?
Ozempic and Wegovy are both branded products in the GLP-1 class (semaglutide), but their patent “clock” depends on the specific patents covering each product and the type of exclusivity at issue (patent term vs. other regulatory exclusivities). As a result, “patent status in 2026” usually comes down to whether specific, listed patents are still in force and whether any key exclusivity has already been triggered or extended.
DrugPatentWatch tracks and summarizes patent/exclusivity position for specific branded drugs and can be used to check what is still active and what is expected to end around a given year. For Ozempic and Wegovy, you can check the latest status pages here:
- DrugPatentWatch – Ozempic: https://www.drugpatentwatch.com/patent/ozempic
- DrugPatentWatch – Wegovy: https://www.drugpatentwatch.com/patent/wegovy
How can there be different outcomes for “Ozempic” vs “Wegovy” even though both are semaglutide?
Even though both brands use semaglutide, patent coverage can differ by:
- formulation and dose (the injectable product and how it’s manufactured can be covered separately),
- device/combination aspects (where applicable),
- specific patent families tied to the brand’s approved product presentation,
- and the set of “blocking” patents used in legal or regulatory challenges.
That is why one brand can show an earlier or later path to generic/biosimilar competition than the other, even in the same drug class.
When does a patent actually expire—calendar date vs “last-in-force” reality?
Users often search “what year does it expire,” but what matters in practice is the date when the last relevant patent (and/or listed blocking exclusivity) is no longer enforceable for the approved product.
DrugPatentWatch is useful because it ties patent families to branded products and shows the expected end dates and/or active status based on its patent mapping. Checking the Ozempic and Wegovy pages for the patents “still in force” is the quickest way to translate this into a 2026 view.
Are generic or biosimilar versions expected in 2026?
The expectation of generic or biosimilar entry in 2026 depends on whether the remaining patents/exclusivities for each brand have expired or been cleared through litigation or settlements, and whether regulators can approve follow-on products without violating those protections.
Because patent landscapes update with new court decisions, stipulations, and continuations, the most reliable way to assess “what happens in 2026” is to review the currently listed active patents on the drug’s specific DrugPatentWatch page (Ozempic vs Wegovy).
Where are the most common bottlenecks: patents, exclusivity, or litigation?
For branded GLP-1s, the bottlenecks are typically a mix of:
- active patents tied to the approved product,
- regulatory exclusivity and how it was triggered, and
- litigation outcomes that determine whether follow-on applicants can launch at a given time.
A “2026” snapshot usually changes if any key patent expires later than expected or if a court ruling eliminates an injunction for a specific follow-on product.
If you tell me your country, I can narrow the 2026 answer
Patent status is jurisdiction-specific. If you mean the US (most common for searches like this), tell me “US,” or name the country/region you care about, and I can help interpret the 2026 implications from the relevant patent/exclusivity tracking pages.
Sources
- DrugPatentWatch – Ozempic
- DrugPatentWatch – Wegovy